Zelapar FDA Approval History
FDA Approved: Yes (First approved June 14, 2006)
Brand name: Zelapar
Generic name: selegiline hydrochloride
Dosage form: Orally Disintegrating Tablets
Company: Valeant Pharmaceuticals International
Treatment for: Parkinson's Disease
Zelapar (selegiline) is an an irreversible inhibitor of monoamine oxidase (MAO) indicated as an adjunct in the management of patients with Parkinson’s disease.
Development timeline for Zelapar
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
